Moomoo AI 已提取核心信息
180 Life Sciences Corp. has filed a prospectus supplement on February 28, 2024, to update and amend its previous prospectus dated May 12, 2023. The supplement includes information from the company's Current Reports filed on February 20, 26, and 28, 2024, with the SEC. A significant update disclosed is the 1-for-19 reverse stock split of the company's common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. The last reported sale price of the company's common stock on Nasdaq was $0.195 per share on February 27, 2024. Additionally, the company has won a Motion for Partial Summary Judgment against its insurers, AmTrust and Freedom, which are now required to advance defense costs related to SEC subpoenas to the company's former executives. The trial is scheduled for May 12, 2025. Furthermore, the company announced the exercise of pre-funded warrants resulting in the issuance of 1,111,878 shares of common stock. Post-issuance, the company will have 11,270,710 shares of common stock outstanding. The reverse stock split is intended to help the company meet Nasdaq's minimum bid price requirement for continued listing.
180 Life Sciences Corp. has filed a prospectus supplement on February 28, 2024, to update and amend its previous prospectus dated May 12, 2023. The supplement includes information from the company's Current Reports filed on February 20, 26, and 28, 2024, with the SEC. A significant update disclosed is the 1-for-19 reverse stock split of the company's common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. The last reported sale price of the company's common stock on Nasdaq was $0.195 per share on February 27, 2024. Additionally, the company has won a Motion for Partial Summary Judgment against its insurers, AmTrust and Freedom, which are now required to advance defense costs related to SEC subpoenas to the company's former executives. The trial is scheduled for May 12, 2025. Furthermore, the company announced the exercise of pre-funded warrants resulting in the issuance of 1,111,878 shares of common stock. Post-issuance, the company will have 11,270,710 shares of common stock outstanding. The reverse stock split is intended to help the company meet Nasdaq's minimum bid price requirement for continued listing.
180 Life Sciences Corp. 已于2024年2月28日提交了招股说明书补充文件，以更新和修改其先前于2023年5月12日的招股说明书。该补充文件包括该公司于2024年2月20日、26日和28日向美国证券交易委员会提交的最新报告中的信息。披露的一项重大更新是公司普通股的反向股票分割比例，自美国东部时间2024年2月28日凌晨 12:01 起生效。2024年2月27日，该公司在纳斯达克上次公布的普通股销售价格为每股0.195美元。此外，该公司还赢得了针对其保险公司AmTrust和Freedom的部分即决判决动议，这两家保险公司现在需要向该公司前高管预付与美国证券交易委员会传票有关的辩护费用。该审判定于2025年5月12日进行。此外，该公司宣布行使预先注资的认股权证，从而发行了1,111,878股普通股。发行后，该公司将有11,270,710股已发行普通股。反向股票拆分旨在帮助该公司满足纳斯达克继续上市的最低出价要求。
180 Life Sciences Corp. 已于2024年2月28日提交了招股说明书补充文件，以更新和修改其先前于2023年5月12日的招股说明书。该补充文件包括该公司于2024年2月20日、26日和28日向美国证券交易委员会提交的最新报告中的信息。披露的一项重大更新是公司普通股的反向股票分割比例，自美国东部时间2024年2月28日凌晨 12:01 起生效。2024年2月27日，该公司在纳斯达克上次公布的普通股销售价格为每股0.195美元。此外，该公司还赢得了针对其保险公司AmTrust和Freedom的部分即决判决动议，这两家保险公司现在需要向该公司前高管预付与美国证券交易委员会传票有关的辩护费用。该审判定于2025年5月12日进行。此外，该公司宣布行使预先注资的认股权证，从而发行了1,111,878股普通股。发行后，该公司将有11,270,710股已发行普通股。反向股票拆分旨在帮助该公司满足纳斯达克继续上市的最低出价要求。
有用
没用
